Carrier-Free Liposome Pneumococcal Vaccine Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pneumococcal vaccines that use pneumococcal capsular polysaccharides conjugated with carrier proteins, such as diphtheria toxoid, may induce asthma-like side effects in children and are costly due to the need for carrier proteins, which also act as allergens.
Innovation Solution
A vaccine composition using pneumococcal capsular polysaccharide-encapsulated liposomes without carrier proteins, made of specific phospholipids like phosphatidylcholine and cholesterol, which enhance immunogenicity and can be produced more economically and safely.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pneumococcal capsular polysaccharides are conjugated with carrier proteins (e.g., diphtheria toxoid), then immunogenicity is enhanced and T cell stimulation is improved, but the risk of inducing asthma and allergic reactions increases
Solution Approach 1:
The invention extracts and removes the carrier protein component from the vaccine system while retaining the essential immunogenic function through liposome encapsulation. The pneumococcal capsular polysaccharides are encapsulated in liposomes without conjugation to carrier proteins, eliminating the source of allergic reactions while maintaining immunogenicity through the liposome delivery system
Solution Approach 2:
The invention changes the fundamental parameter of vaccine architecture from protein-conjugate to liposome-encapsulated polysaccharide. This parameter change transforms the delivery mechanism from relying on carrier protein T cell stimulation to utilizing liposome-mediated antigen presentation, thereby eliminating asthma induction risk while preserving immunogenicity
2Reliability
If carrier proteins are used in pneumococcal vaccines, then immunogenicity is improved, but production costs increase due to the need for additional protein components
Solution Approach 1:
The invention extracts the carrier protein component from the vaccine formulation, eliminating the need for complex protein production, purification, and conjugation processes. Only the pneumococcal capsular polysaccharides and liposome components are required, significantly simplifying manufacturing and reducing costs
Solution Approach 2:
The invention replaces expensive carrier proteins with a simpler, more cost-effective liposome delivery system. The liposomes serve as temporary carriers that facilitate antigen delivery without requiring the complex biochemical structures and expensive production processes associated with carrier proteins
3Reliability
If carrier proteins are included in vaccine composition, then T cell stimulation is enhanced, but the complexity of vaccine formulation increases
Solution Approach 1:
The invention removes the carrier protein component from the formulation, eliminating the need for complex conjugation chemistry and multi-component formulation. The simplified system uses only polysaccharide antigens encapsulated in liposomes, reducing formulation complexity while maintaining immunogenicity
Solution Approach 2:
The liposome delivery system performs multiple functions simultaneously: it protects the polysaccharide antigens, facilitates cellular uptake, enables antigen presentation, and eliminates the need for carrier proteins. This multi-functional approach simplifies the overall formulation while achieving the desired immunogenic效果
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vaccine composition effectively elicits immunity against pneumococcal infections with higher antibody production compared to conventional vaccines, reducing the risk of allergic reactions and production costs.
Implementation Method 1
a liposome with a specific phospholipid and cholesterol composition enhances the immunogenicity of pneumococcal capsular polysaccharides sufficiently not to recruit a carrier protein
Implementation Method 2
A liposome is an artificially prepared vesicle composed of phospholipids, found in biological membranes
Implementation Method 3
said liposomes containing no carrier proteins and being made of: a phospholipid selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine and a combination thereof; and a cholesterol selected from the group consisting of cholesterol, cholesterol hemisuccinate, a derivative thereof, and a combination thereof
Data Source
Figure 1
Figure 2
Figure 3a
AI summary
The present invention relates to a liposome composition including liposomes encapsulated with a pneumococcal capsular polysaccharide antigen, a method of preparing the composition, and a usage of the composition as a pneumonia vaccine, wherein the liposome composition comprises: a phospholipid selected from phosphatidylcholine and phosphatidylethanolamine; and a cholesterol or derivative thereof selected from cholesterol and cholesterol hemisuccinate, wherein the liposome does not include a carrier protein.